MARCoNS: Understanding the Nasal Biofilm Infection Linked to Chronic Illness

<![CDATA[

What Is MARCoNS?

MARCoNS — Multiple Antibiotic Resistant Coagulase Negative Staphylococci — is a type of antibiotic-resistant bacterial infection that colonizes the deep nasal passages. While often dismissed as an inconsequential commensal organism by conventional medicine, MARCoNS has gained significant clinical attention in the treatment of chronic inflammatory illnesses, particularly Chronic Inflammatory Response Syndrome (CIRS), mold illness, and Lyme disease.

What makes MARCoNS clinically important is not the bacteria itself, but its relationship to the broader inflammatory cascade. MARCoNS produces biofilm — a protective slime layer that allows it to persist deep within the nasal cavity — and certain strains produce hemolysins and other toxins that can fragment Melanocyte Stimulating Hormone (MSH), a critical regulatory neuropeptide. The resulting MSH deficiency has far-reaching consequences for immune regulation, sleep, pain perception, and mood.

At St. George Hospital in Bad Aibling, Germany, we encounter MARCoNS frequently in patients with chronic, multi-system illness. Dr. Julian Douwes and our medical team include MARCoNS evaluation as part of our comprehensive diagnostic approach for patients whose conditions have proven resistant to conventional treatment.

The Biology of MARCoNS

Coagulase-Negative Staphylococci

Coagulase-negative staphylococci (CoNS) are a group of Staphylococcus species that lack the coagulase enzyme produced by the more notorious Staphylococcus aureus. Common CoNS species include Staphylococcus epidermidis, Staphylococcus hominis, and Staphylococcus lugdunensis. These organisms are ubiquitous residents of human skin and mucous membranes.

Under normal circumstances, CoNS are kept in check by a healthy immune system and compete with other commensal organisms for ecological niches. However, when the immune system is compromised — as it often is in patients with chronic infection, mold exposure, or biotoxin illness — these organisms can proliferate, develop antibiotic resistance, and establish persistent biofilm colonies in the deep nasal passages.

Multiple Antibiotic Resistance

The “MAR” in MARCoNS refers to resistance against two or more classes of antibiotics. This resistance develops through a combination of genetic mutation, horizontal gene transfer (sharing resistance genes between bacterial species), and selection pressure from antibiotic exposure. The practical consequence is that standard antibiotic therapy is ineffective against established MARCoNS colonies.

Biofilm Formation

Perhaps the most clinically significant characteristic of MARCoNS is its capacity to form robust biofilms within the nasal passages. Biofilms are organized bacterial communities encased in a protective extracellular matrix of polysaccharides, proteins, and extracellular DNA. This matrix:

Shields bacteria from antibiotics (biofilm bacteria can tolerate 100–1,000 times the antibiotic concentration required to kill planktonic bacteria)
Protects against immune cell attack
Enables chronic persistence despite treatment attempts
Serves as a reservoir for ongoing toxin production

MSH Degradation

Certain MARCoNS strains produce hemolysins — toxins that lyse red blood cells — and other enzymes capable of degrading alpha-Melanocyte Stimulating Hormone (alpha-MSH). This neuropeptide, produced in the hypothalamus and other tissues, plays regulatory roles in:

Immune regulation: MSH modulates inflammatory cytokine production
Sleep-wake cycle: MSH influences circadian rhythm and sleep quality
Pain modulation: MSH helps regulate pain perception
Mucosal defense: MSH supports the antimicrobial function of mucosal surfaces
Mood regulation: MSH interacts with brain circuits governing mood and motivation

When MARCoNS depletes MSH, the downstream effects include disrupted sleep, increased pain sensitivity, impaired immune regulation, and worsened systemic inflammation — symptoms that are characteristic of CIRS and chronic Lyme disease.

The Connection to Mold Illness and CIRS

MARCoNS gained clinical prominence through the work of Dr. Ritchie Shoemaker, who identified it as a frequent finding in patients with Chronic Inflammatory Response Syndrome (CIRS) — a multi-system inflammatory condition triggered by biotoxin exposure, most commonly from water-damaged buildings (mold illness).

In the CIRS model, the relationship between MARCoNS and mold illness is bidirectional:

Mold exposure compromises immunity: Biotoxins from mold (mycotoxins) trigger a cascade of immune dysregulation, including reduced MSH production
Low MSH allows MARCoNS colonization: Without adequate MSH, the nasal mucosa’s antimicrobial defenses are weakened, allowing MARCoNS to establish biofilm colonies
MARCoNS further depletes MSH: The bacteria’s toxins degrade remaining MSH, creating a vicious cycle
Sustained inflammation: The combined effect of biotoxin burden and MARCoNS-mediated MSH deficiency maintains chronic systemic inflammation

A study published in Research Committee on Medical Mycology and related research has documented the high prevalence of multi-drug resistant nasal staphylococci in patients with chronic inflammatory conditions, supporting the clinical relevance of MARCoNS testing.

The Connection to Lyme Disease

Patients with chronic Lyme disease frequently harbor MARCoNS, likely due to the immune dysregulation caused by persistent Borrelia infection and associated co-infections. The presence of MARCoNS in Lyme patients may contribute to:

Treatment resistance — systemic inflammation maintained by MARCoNS can impair the immune system’s ability to clear Borrelia
Persistent fatigue and cognitive dysfunction through MSH depletion
Sleep disruption that impedes recovery
Ongoing inflammatory burden that complicates clinical improvement

At St. George Hospital, we consider MARCoNS evaluation an important component of the diagnostic workup for patients with chronic Lyme disease who are not responding adequately to antimicrobial therapy.

Testing for MARCoNS

The Nasal Swab

MARCoNS testing requires a deep nasal swab — not a standard nasal culture. The swab must reach the deep nasal passages (near the posterior nasopharynx) to sample the area where MARCoNS biofilm colonies reside. A superficial swab of the anterior nares will miss the pathological colonization.

The swab is submitted to a specialized laboratory that performs:

Culture and identification: Isolation of coagulase-negative staphylococci from the specimen
Antibiotic sensitivity testing: Determination of resistance patterns across multiple antibiotic classes
Biofilm assessment: Evaluation of biofilm-forming capacity

A positive MARCoNS result requires identification of CoNS with resistance to two or more antibiotic classes from the deep nasal specimen.

Complementary Testing

MARCoNS testing is most meaningful when interpreted alongside other CIRS and chronic illness biomarkers:

MSH levels: Low MSH supports the clinical significance of MARCoNS colonization
VIP (Vasoactive Intestinal Peptide): Often low in CIRS patients
MMP-9 (Matrix Metalloproteinase-9): Elevated in active CIRS
TGF-beta-1: Often markedly elevated in CIRS/mold illness
C4a: Inflammatory complement marker
HLA-DR genotyping: Identifies genetic susceptibility to biotoxin illness

Our diagnostic laboratory at St. George Hospital can coordinate comprehensive CIRS biomarker panels alongside MARCoNS testing for patients with suspected biotoxin or chronic inflammatory illness.

Treatment of MARCoNS

BEG Spray (Bactroban/EDTA/Gentamicin)

The most widely used treatment for MARCoNS is BEG spray — a compounded nasal spray containing:

Bactroban (mupirocin): An antibiotic with activity against staphylococci, applied topically to achieve high local concentrations
EDTA (ethylenediaminetetraacetic acid): A chelating agent that disrupts biofilm structure by binding calcium and other metal ions essential for biofilm integrity
Gentamicin: An aminoglycoside antibiotic providing additional antibacterial activity

The combination of biofilm disruption (EDTA) with topical antibiotics (mupirocin and gentamicin) addresses the two main challenges of MARCoNS treatment — the protective biofilm and the antibiotic-resistant bacteria within it.

Typical protocol: Two sprays in each nostril, twice daily, for 30 days. Some patients require longer courses or repeated treatments.

Complementary Approaches

Additional strategies that support MARCoNS eradication include:

Colloidal silver nasal spray: Used as an adjunct or alternative in some protocols
Xylitol nasal spray: Creates an osmotic environment hostile to bacterial biofilm
Nasal probiotic rinses: Competitive colonization with beneficial bacteria
Systemic biofilm disruption: Enzymes such as nattokinase and serrapeptase that may help degrade biofilm components

Addressing the Underlying Cause

Successfully treating MARCoNS requires more than eradicating the nasal colonization — the underlying immune dysfunction that allowed MARCoNS to establish must also be addressed. Without correcting the root cause, recolonization is likely.

At St. George Hospital, our approach includes:

Mold/biotoxin avoidance and remediation: If environmental mold exposure is identified as a trigger
Treatment of underlying infections: Comprehensive management of Lyme disease and co-infections
Immune restoration: Ozone therapy, immune-supportive infusions, and targeted immunomodulation
MSH restoration: Addressing the factors that suppress MSH production
Post-treatment verification: Repeat nasal swab culture after treatment completion to confirm eradication

Our Approach at St. George Hospital

Dr. Julian Douwes and our team view MARCoNS not as an isolated finding but as one component of a complex multi-system illness that requires comprehensive evaluation and treatment. Our approach includes:

Thorough clinical history focusing on mold exposure, tick-borne illness, and environmental triggers
Comprehensive laboratory assessment including MARCoNS culture, CIRS biomarkers, and infection panels
Individualized treatment targeting both the MARCoNS colonization and the underlying immune dysfunction
Integration with broader treatment programs for chronic fatigue, Lyme disease, or post-COVID syndrome
Follow-up testing to confirm treatment success and prevent recurrence

Frequently Asked Questions About MARCoNS

Is MARCoNS contagious?

Coagulase-negative staphylococci are normal inhabitants of human skin and mucous membranes — most people carry them without issue. The MARCoNS colonization pattern (deep nasal biofilm with antibiotic resistance) develops in response to individual immune dysfunction rather than through person-to-person transmission. While the bacteria themselves can theoretically transfer between individuals, developing pathological MARCoNS colonization requires the predisposing immune conditions. Close household contacts do not typically require treatment unless they also have chronic inflammatory illness.

Can MARCoNS come back after treatment?

Yes. If the underlying immune dysfunction that allowed MARCoNS to establish is not adequately addressed, recolonization is common. Successful long-term eradication requires treating the root cause — whether that is mold illness, chronic infection, or other immune-compromising factors — in addition to the nasal colonization itself. Post-treatment follow-up testing is essential to confirm eradication and detect early recolonization.

Do I need to treat MARCoNS if I feel fine?

MARCoNS is clinically significant primarily in the context of chronic inflammatory illness. If MARCoNS is identified incidentally in a patient without symptoms or inflammatory biomarker abnormalities, the clinical significance is less clear. In symptomatic patients with elevated inflammatory markers and low MSH, treatment of MARCoNS is an important component of the recovery pathway. The decision to treat should be made in the context of the full clinical picture.

How long does it take to clear MARCoNS?

Standard BEG spray protocols run for 30 days. Some patients clear MARCoNS with a single course; others require extended or repeated treatment, particularly if biofilm formation is extensive or if underlying immune dysfunction persists. A study on biofilm-associated nasal infections highlighted the importance of biofilm disruption strategies in achieving successful eradication. Follow-up culture 4–6 weeks after completing treatment confirms whether eradication was achieved.

Is MARCoNS recognized by mainstream medicine?

MARCoNS as a clinical entity is primarily recognized within the integrative and environmental medicine communities, particularly among physicians treating CIRS and chronic Lyme disease. Mainstream infectious disease specialists may be less familiar with the specific clinical framework, though the underlying science — antibiotic-resistant nasal biofilm colonization and its immunological consequences — is grounded in established microbiology. Research in this area continues to evolve.

Get Tested and Treated for MARCoNS

If you are dealing with chronic illness that has not responded to conventional treatment — particularly if you have a history of mold exposure, tick-borne infection, or CIRS — MARCoNS evaluation may provide important diagnostic clarity. At St. George Hospital, we integrate MARCoNS testing into our comprehensive approach to complex chronic illness.

Contact our international patient team:

This article is for informational purposes only and does not constitute medical advice. MARCoNS testing and treatment should be conducted under qualified medical supervision. Individual results may vary.

]]>

Considering Lyme Treatment?

Learn about our comprehensive Lyme disease treatment program and whether it may be right for you.